Pulmonary arterial hypertension [[electronic resource] ] : diagnosis and evidence-based treatment / / edited by Robyn J. Barst

• Pubblicazione: Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008
• Descrizione fisica: 1 online resource (280 p.)
• Disciplina: 616.132; 616.2/4
• Soggetto topico: Pulmonary hypertension; Evidence-based medicine
• Altri autori: BarstRobyn J <1950-> (Robyn Joan)
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Pulmonary Arterial Hypertension; Contents; Preface; Contributors; 1 Introduction; 2 Diagnosis and assessment of pulmonary arterial hypertension; 2.1 Hemodynamics of pulmonary hypertension; 2.2 Venice classification; 2.3 Overview of the diagnostic process (algorithm); 2.4 Screening (identifying a pre-existing risk); 2.5 Detection (discovering pulmonary hypertension); 2.6 Definition (diagnosing the clinical context); 2.7 Prediction (estimating prognosis); 2.8 Principles of follow-up (evaluating and responding to outcome); 2.9 Specific tests in the evaluation of pulmonary hypertension ; 3 Conventional therapy in pulmonary arterial hypertension3.1 Calcium channel antagonists; 3.2 Diuretics; 3.3 Warfarin; 3.4 Supplemental oxygen; 3.5 Inotropic therapy; 3.6 General measures; 3.7 Conclusions; 4 Prostanoid treatment for pulmonary arterial hypertension; 4.1 Epoprostenol; 4.2 Treprostinil; 4.3 Iloprost; 4.4 Beraprost; 4.5 Treatment selection; 4.6 Conclusions; 5 Endothelin receptor antagonists in pulmonary arterial hypertension; 5.1 Bosentan; 5.2 Sitaxsentan; 5.3 Ambrisentan; 5.4 Safety and tolerability with endothelin receptor antagonists; 5.5 Conclusions ; 6 Phosphodiesterase-5 inhibitors in pulmonary arterial hypertension6.1 The origins of phosphodiesterase-5 inhibitor development; 6.2 Pulmonary hypertension as a new indication for phosphodiesterase-5 inhibitor treatment; 6.3 Role of phosphodiesterase-5 in the pulmonary vasculature; 6.4 Clinical experience with sildenafil for the treatment of chronic pulmonary hypertension; 6.5 Pivotal trial and approval of sildenafil for the treatment of pulmonary arterial hypertension (SUPER-1 study); 6.6 Other phosphodiesterase-5 inhibitors; 6.7 Combination therapy ; 6.8 Potential new indications for phosphodiesterase-5 inhibitors outside pulmonary arterial hypertension6.9 Conclusions; 7 Combination therapy for pulmonary arterial hypertension; 7.1 Background; 7.2 Combination therapy to date; 7.3 Conclusions; 8 Interventional and surgical modalities of treatment for pulmonary arterial hypertension; 8.1 Introduction; 8.2 Atrial septostomy; 8.3 Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension; 8.4 Lung transplantation for pulmonary hypertension; 8.5 Conclusions ; 9 End points and clinical trial design in pulmonary arterial hypertension: Clinical and regulatory perspectives9.1 Introduction; 9.2 Trial design; 9.3 End points in trials of therapy for pulmonary arterial hypertension; 9.4 Conclusions; 10 Comparative analysis of clinical trials and evidence-based treatment algorithm for pulmonary arterial hypertension; 10.1 Introduction; 10.2 Randomized controlled studies; 10.3 Long-term continuation studies; 10.4 Combination studies; 10.5 Evidence-based treatment algorithm; 10.6 Conclusions ; 11 Diagnosis and assessment of non-pulmonary arterial hypertension masquerading as idiopathic pulmonary arterial hypertension: Diastolic heart failure - evaluation and interactions
• Sommario/riassunto: First book dedicated to this disease, previously thought to be incurable, but with the advent of new drugs, now amenable to management and a much improved prognosis for patientsFrom the PAH Association, the leading experts in fieldIncorporates the latest AACP management guidelinesIncludes evidence-based treatment algorithms based on the recently updated ACCP Guidelines for Medical TreatmentAimed at specialists in pulmonology and cardiovascular disease, this volume provides the clinician with the most up to date information on the effective management of PAH
• Titolo autorizzato: Pulmonary arterial hypertension
• ISBN: 1-281-84133-1; 9786611841331; 0-470-99739-7; 0-470-99738-9
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910144119603321
• Lo trovi qui: Univ. Federico II